23103-35-7
Chemical Structure
myo-Inositol trispyrophosphate hexasodium
Synonym(s): ITPP hexasodium
- CAS No.: 23103-35-7
- Formula:C6H6Na6O21P6
- Molecular Weight:737.88
IUPAC Name: sodium (5aR,5bS,10aS,10bS,15aS,15bS)-hexahydrobenzo[1,2-f:3,4-f':5,6-f'']tris([1,3,5,2,4]trioxadiphosphepine)-2,4,7,9,12,14-hexakis(olate) 2,4,7,9,12,14-hexaoxide
InChIKey: DTOYSAZRROROSE-JFDZSQFASA-H
SMILES: O=P1(O[C@]2([H])[C@@]3([H])[C@@](OP(OP(O3)(O[Na])=O)(O[Na])=O)([H])[C@]4([H])[C@@](OP(OP(O4)(O[Na])=O)(O[Na])=O)([H])[C@@]2([H])OP(O1)(O[Na])=O)O[Na]
Biological Activity: myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
myo-Inositol trispyrophosphate hexasodium | 95.0% | myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Oknińska M, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283. [Content Brief]
- [2]. Raykov Z, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82. [Content Brief]
- [3]. Fylaktakidou KC, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8. [Content Brief]
